Business
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $182.1 million cash, cash equivalents and restricted cash as of March 31, 2025
About this update from Cartesian Therapeutics, Inc.
[{"type":"image","alt":"Cartesian Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cartesian Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/d8abef5500410e9a7353f02873aa8d43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vlOyY4EEsvNCPN1.1VEVug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d8abef5500410e9a7353f02873aa8d43","width":300,"height":75}},"lazy":false},{"type":"text","content":"Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial","length":194,"tagName":"p"},{"type":"text","content":" Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 ","length":100,"tagName":"p"},{"type":"text","content":"Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25","length":110,"tagName":"p"},{"type":"text","content":"Approximately $182.1 million cash, cash equivalents and restricted cash as of March 31, 2025 expected to support planned operations into mid-2027, including completion of planned Phase 3 AURORA trial","length":199,"tagName":"p"},{"type":"text","content":"FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025, and outlined recent corporate updates.","length":313,"tagName":"p"},{"type":"text","content":"“We are off to a strong start in what we expect to be a productive year marked by several potential value-creating milestones across our pipeline,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “This includes the recent presentation of updated data from our Phase 2b trial of Descartes-08 in participants with myasthenia gravis (MG), in which we observed deep and sustained benefits at Month 12 following a single course of therapy, particularly in participants without exposure to prior biologic therapies. These data underscore the potential of Descartes-08, which is designed to be dosed co...